Physician

Ali Ahmad Suleiman, MD

According to 2025 Medicare claims, Ali Suleiman, MD (NPI: 1720167687) practices nephrology in the Beckley, WV market, with the plurality of this provider's patient population coming from Raleigh, WV. This provider's primary affiliated billing organization is ALI SULEIMAN MD INC (NPI: 1861693202; TIN: 421635246) and primary practice location at 25801-9008. Suleiman is affiliated with the ACO West Virginia (ACO ID: A3563) and Main Street Rural Health Sycamore ACO LLC (ACO ID: A5403), participating under the MSSP model.

Suleiman's data goes back to 2015 and runs through 2024. For example, in 2024, this provider had 322 traditional Medicare patients, billed 2,022 HCPCS/CPT codes, and received $232,261 in Medicare payments. The top billing code was 90960 (Dialysis services, 4 or more physician visits per month (20 years or older)). Part D data shows 1,356 prescription claims across 202 beneficiaries totaling $310,112 in drug costs, led by Velphoro (Sucroferric Oxyhydroxide). DME data shows 60 claims. Open Payments data shows 6 records totaling $146. You can download detailed data with all billing codes (2015-2024). For more recent data, please contact us.

Over the past 10 years, this provider's Medicare Part B carrier billing has moved up and down with repeated peaks and valleys, starting at $469,682 and ending at $232,261. Concurrently, Part D prescription costs have declined steadily, from $472,652 to $310,112. For DME billing, this provider has fewer than 5 years of reported data, so a reliable trend cannot be assigned.

Part B Carrier Billing Trend

Medicare payment trend, with N of patients and claim lines in the table.

Year	Patients	Clm Lines	Payment
2015	755	6,037	$469,682
2016	699	4,835	$414,957
2017	768	4,868	$541,368
2018	726	5,126	$424,732
2019	871	6,659	$550,877
2020	848	7,008	$582,664
2021	671	4,812	$469,645
2022	392	2,809	$307,829
2023	445	3,021	$306,944
2024	322	2,022	$232,261

Part D Events Trend

Drug cost trend, with N of patients and prescription claims in the table.

Year	Patients	Claims	Drug Cost
2015	346	4,025	$472,652
2016	337	4,078	$670,031
2017	322	3,573	$714,343
2018	286	2,541	$411,348
2019	306	2,634	$431,675
2020	283	2,420	$479,261
2021	260	2,003	$444,284
2022	224	1,929	$411,763
2023	224	1,804	$398,659
2024	202	1,356	$310,112

DME Billing Trend

Medicare payment trend, with N of patients and DME claim records in the table.

Year	Patients	Claims	Payment
2015	N/R	236	$12,819
2016	N/R	185	$14,308
2017	N/R	154	$8,573
2018	N/R	128	$8,532
2019	N/R	96	$5,426
2020	N/R	137	$9,339
2021	N/R	70	$2,468
2022	N/R	70	$1,745
2023	N/R	54	$1,241
2024	N/R	60	$1,750

* / # = suppressed by CMS; 0 = reported zero; N/R = not reported or blank.

Top 5 Part B carrier billing codes in 2024

By total payments.

Code	Description	Patients	Clm Lines	Total Payment
90960	Dialysis services, 4 or more physician visits per month (20 years or older)	53	330	$265
99223	Initial hospital care with moderate level of medical decision making, if using time, at least 75 minutes	51	52	$131
99222	Initial hospital care with straightforward or low-level medical decision making, if using time, at least 55 minutes	133	191	$98
99214	Established patient office or other outpatient visit with moderate level of decision making, if using time, 30 minutes or more	108	258	$91
99232	Subsequent hospital care with moderate levelof medical decision making, if using time, at least 35 minutes	171	817	$60

Top 5 Part D drugs in 2024

By total drug costs.

Drug	Generic	Claims	Total Day Supply	Total Drug Cost
Velphoro	Sucroferric Oxyhydroxide	76	2,670	$203,486
Auryxia	Ferric Citrate	20	1,088	$33,860
Sevelamer Carbonate	Sevelamer Carbonate	170	7,373	$16,904
Farxiga	Dapagliflozin Propanediol	11	450	$8,372
Lokelma	Sodium Zirconium Cyclosilicate	13	388	$5,980

Top 5 DME services in 2024

By Total Medicare Payment Amount.

HCPCS Code	HCPCS Description	Supplier Rental Indicator	Total Supplier Beneficiaries	Total Supplier Claims	Total Medicare Payment Amount
J7518	Mycophenolic acid, oral, 180 mg	N	N/R	23	$1,211
Q0511	Pharmacy supply fee for oral anti-cancer, oral anti-emetic or immunosuppressive drug(s); for the first prescription in a 30-day period	N	N/R	17	$301
Q0512	Pharmacy supply fee for oral anti-cancer, oral anti-emetic or immunosuppressive drug(s); for a subsequent prescription in a 30-day period	N	N/R	20	$238

Open Payments Summary in 2024

Category	Definition	Records	Total Reported Amount	Top Related Entity
General Payments	Reported payment or transfer-of-value amount.	6	$146	Novo Nordisk Inc
Research Payments	Reported research-related payment or transfer-of-value amount.	0	$0	N/R
Ownership / Investment Interests	Reported value of ownership or investment interests.	0	$0	N/R

Explore More Providers

FAQ

What Medicare data is available for Ali Ahmad Suleiman, MD?

Tedicare shows public-source Medicare data for Ali Ahmad Suleiman, MD (NPI 1720167687), including provider identity, specialty, market context, Medicare Part B activity, Part D prescribing, DME records, Open Payments where available, billing organization details, and ACO affiliation signals where available. Profile data covers 2015-2024, with current attribution based on 2025 claims where available.

Does Ali Ahmad Suleiman, MD have ACO affiliation data?

Ali Ahmad Suleiman, MD is shown with ACO affiliation data for ACO West Virginia (MSSP, ACO ID A3563) and Main Street Rural Health Sycamore ACO LLC (MSSP, ACO ID A5403).

What billing organization is linked to Ali Ahmad Suleiman, MD?

Ali Ahmad Suleiman, MD is linked to ALI SULEIMAN MD INC (billing NPI 1861693202) in the available physician profile data.

Does Ali Ahmad Suleiman, MD have Open Payments data?

Ali Ahmad Suleiman, MD has 6 connected Open Payments records in the available 2024 summary data.

Can I download physician-level Medicare data from Tedicare?

Yes. Tedicare provides sample physician export data and paid custom physician data exports for research, planning, outreach, and market analysis. Exports can include physician profile fields, market and specialty context, billing organization details, ACO affiliation signals where available, and Medicare utilization data.